Table 5.
Baseline patient-reported outcome measures for patients with plaque psoriasis and concomitant dermatologist-diagnosed psoriatic arthritis who initiated guselkumab in CorEvitas’ Psoriasis Registry by prior biologic use
| Characteristicsa | Prior biologic useb (n) | Standardized differencec | |
|---|---|---|---|
| Biologic-naïve (n = 17) | Biologic-experienced (n = 234) | ||
| Overall patient-reported outcomes, mean (SD) | |||
| Overall itch/pruritus (VAS 0–100) | 76.9 (21.5) | 54.1 (33.5) | 0.81 |
| Overall fatigue (VAS 0–100) | 50.6 (27.9) | 44.8 (31.1) | 0.20 |
| Overall skin pain (VAS 0–100) | 53.7 (30.9) | 40.8 (33.4) | 0.40 |
| PGA (VAS 0–100) | 66.6 (18.9) | 50.3 (27.7) | 0.69 |
| PsA patient-reported outcomes, n | 16 | 206 | |
| Joint pain due to PsA (VAS 0–100), mean (SD) | 49.9 (28.5) | 45.6 (32.1) | 0.14 |
| Wellness as a result of PsA (VAS 0–100), mean (SD) | 52.6 (28.8) | 43.2 (30.2) | 0.32 |
| WPAI, mean (SD) | |||
| Currently employed, n (%) | 12 (70.6) | 150 (64.1) | 0.14 |
| % of work hours missed due to PsO |
n = 10 4.3 (11.7) |
n = 132 5.8 (17.8) |
0.10 |
| % of impairment while working due to PsO |
n = 10 35.5 (28.9) |
n = 130 16.8 (24.1) |
0.70 |
| % of work hours affected by PsO |
n = 10 37.8 (30.3) |
n = 129 18.3 (26.1) |
0.69 |
| % of daily activities impaired by PsO |
n = 16 40.9 (26.9) |
n = 229 29.1 (30.0) |
0.41 |
| DLQI (score 0–30), mean (SD) | 11.4 (4.8) | 8.6 (6.5) | 0.49 |
| DLQI “effect on life”, n (%) | 0.73 | ||
| 0–1: none | 0 (0.0) | 29 (12.6) | |
| 2–5: small | 2 (11.8) | 61 (26.4) | |
| 6–10: moderate | 6 (35.3) | 58 (25.1) | |
| 11–20: very large | 8 (47.1) | 69 (29.9) | |
| 21–30: extremely large | 1 (5.9) | 14 (6.1) | |
| EQ-5D VAS (0–100), mean (SD) | 62.2 (17.8) | 67.3 (21.4) | 0.26 |
| ED-5D-3L categorical domains, n (%)d | |||
| Walking | 7 (43.8) | 97 (42.2) | 0.03 |
| Self-care | 1 (6.3) | 36 (15.8) | 0.31 |
| Usual activities | 11 (68.8) | 96 (41.7) | 0.56 |
| Pain and discomfort | 13 (81.3) | 169 (73.5) | 0.19 |
| Anxiety and depression | 4 (25.0) | 95 (41.3) | 0.35 |
| Problems with sleeping | 3 (17.6) | 50 (21.6) | 0.10 |
DLQI Dermatology Life Quality Index, EQ-5D EuroQoL-5 dimensions, EQ-5D-3L EuroQoL-5 dimensions, 3 levels, PsA psoriatic arthritis, PsO psoriasis, SD standard deviation, VAS visual analog scale
aNot all patients provided responses to all patient-reported outcomes; item non-response was < 6% among biologic-naïve patients and < 3% among biologic-experienced patients for all cells, unless denominator is reported. Note that the three WPAI summary scores related to working are applicable only to those who are currently employed
bBiologic medications included adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, secukinumab, and ustekinumab
cMeaningful differences (standardized difference > 0.10) are bolded
dPercentage of patients reporting at least some problem